Abstract:Aim: Tacrolimus, an immunosuppressant used to prevent organ rejection in renal transplant patients, exhibits high inter-patient variability, necessitating therapeutic drug monitoring. Early post-transplant tacrolimus exposure in Hispanics is understudied. Although genotypic information is linked to pharmacokinetic differences, its clinical application remains limited. This study aimed to use a real-world data-driven, pharmacokinetic model-based approach for tacrolimus in Hispanics to determine a suitable initial dose and design an optimal dose titration strategy by simulations to achieve plasma trough concentration target levels of 10-12 ng/mL at the earliest. Methods: Sparse concentration-time data of tacrolimus were obtained from electronic medical records for self-identified Hispanic subjects following renal transplant. Rich pharmacokinetic literature data was leveraged to estimate structural pharmacokinetic model parameters, which were then fixed in the current analysis. Only apparent clearance was estimated with the sparse tacrolimus data and potential covariates were identified. Simulations of various starting doses and different dose titration strategies were then evaluated. Results: The analysis included 121 renal transplant patients with 2,215 trough tacrolimus concentrations. A two-compartment transit absorption model with allometrically scaled body weight and time-varying hematocrit on apparent clearance adequately described the data. The estimated apparent clearance was 13.7 L/h for a typical patient weighing 70 kg and at 30% hematocrit, demonstrating a 40% decrease in clearance compared to other patient populations. Model based simulations indicated the best initial dose for the Hispanic population is 0.1 mg/kg/day. The proposed titration strategy, with three dose adjustments based on trough levels of tacrolimus, increased the proportion of patients within the target range (10-12 ng/mL) more than 2.5-fold and decreased the proportion of patients outside the therapeutic window by 50% after the first week of treatment. Conclusion: Hispanic renal transplant population showed an estimated 40% decrease of apparent clearance in the typical patient compared to other populations with similar characteristics. The proposed dose adjustment attained the target range rapidly and safely. This study advocates for tailored tacrolimus dosing regimens based on population pharmacokinetics to optimize therapy in Hispanic renal transplant recipients.

Case analysis of individualized tacrolimus treatment on patient with nephrotic syndrome

Tacrolimus Combined with Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Trial

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

Early Initiation of Tacrolimus or Cyclophosphamide Therapy for Idiopathic Membranous Nephropathy with Severe Proteinuria.

Population Pharmacokinetics and Dosage Optimization of Tacrolimus in Pediatric Patients with Nephrotic Syndrome

Optimizing tacrolimus dosing in Hispanic renal transplant patients: insights from real-world data

Current Progress of Tacrolimus Dosing in Solid Organ Transplant Recipients: Pharmacogenetic Considerations

Influence Of Cyp3a5 And Mdr1 Polymorphisms On Tacrolimus Concentration In The Early Stage After Renal Transplantation

Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients

Removing the physician from the equation: Patient‐controlled, home‐based therapeutic drug self‐monitoring of tacrolimus

Incorporation of Gene-Environment Interaction Terms Improved the Predictive Accuracy of Tacrolimus Stable Dose Algorithms in Chinese Adult Renal Transplant Recipients

[Population Pharmacokinetics of Tacrolimus in Chinese Renal Transplant Patients].

Gene Polymorphisms of CYP 3AP1 and MDR1 Associated with the Interindividual Variability of Tacrolimus Concentration

Prediction of Tacrolimus Dose/Weight-Adjusted Trough Concentration in Pediatric Refractory Nephrotic Syndrome: A Machine Learning Approach

Effect of CYP3 A4, CYP3 A5 and ABCB1 Gene Polymorphisms on the Clinical Efficacy of Tacrolimus in the Treatment of Nephrotic Syndrome

Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients

Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule

Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome

Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome

Effect of CYP3A4 and CYP3A5 Gene Polymorphisms on Tacrolimus Plasma Concentration in Renal Transplanted Recipients in the Han Population

Initial Dosage Optimization of Tacrolimus in Chinese Pediatric Patients Undergoing Kidney Transplantation Based on Population Pharmacokinetics and Pharmacogenetics